“Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion and value-driven diagnostics. During the period, we also strengthened our speciality portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT,” said CEO, Rahul Guha, as Thyrocare Technologies Limited reported robust financial results for the quarter ended March 31, 2026.
The healthcare diagnostics company delivered strong fourth-quarter growth, supported by sustained momentum in pathology services, network expansion and strategic investments in speciality diagnostics.
Thyrocare reported consolidated revenue of Rs223.95 crore for Q4FY26, reflecting a 20 per cent year-on-year increase, primarily driven by 21 per cent growth in its pathology segment.
The company’s consolidated EBITDA rose 31 per cent year-on-year to Rs75.09 crore, while profit after tax surged 128 per cent to Rs48.70 crore, underscoring improved operational efficiency and profitable growth.
For the full fiscal year FY26, consolidated revenue grew 21 per cent year-on-year to Rs829.04 crore, while EBITDA increased 38 per cent to Rs262.04 crore. Profit after tax rose 81 per cent to Rs162.85 crore.
Thyrocare further reinforced its position as India’s largest diagnostic test volume processor during the quarter, processing 59 million tests in Q4FY26, a 29 per cent year-on-year increase.
Annual test volumes reached 209.6 million in FY26, marking 23 per cent growth over the previous year.
Within its pathology business, franchise revenue expanded 21 per cent year-on-year during the quarter, while partnership revenue grew 23 per cent.
For the full year, franchise revenue rose 18 per cent, while partnership revenue recorded a stronger 32 per cent increase.
A key strategic highlight for the quarter was the company’s expansion into speciality diagnostics.
Thyrocare broadened its test portfolio with more than 250 allergy testing SKUs on the Phadia platform and entered the genomics segment through the launch of non-invasive prenatal testing (NIPT) from its newly established state-of-the-art genomics laboratory.
The company said this phased expansion of its precision diagnostics portfolio is aimed at strengthening clinical offerings and enhancing its position in high-value speciality diagnostics.
Operationally, Thyrocare also reported significant quality improvements.
The company reduced complaints per million tests by 34 per cent year-on-year to 3.1, while achieving an average turnaround time of 3.43 hours from sample receipt.
According to the company, this makes Thyrocare India’s first diagnostic chain to achieve this benchmark while maintaining Six Sigma quality standards.
Guha said the company remains focused on expanding into underserved regions and strengthening its franchise and partner network while continuing to deliver affordable and high-quality diagnostic services across India.
The company’s performance reflects growing demand for diagnostic services, increased penetration of speciality testing and rising adoption of precision diagnostics as India’s healthcare sector continues to evolve.
